
Merck: Keytruda approved for pleural mesothelioma
(CercleFinance.com) - Merck announces that the US FDA has approved its blockbuster Keytruda, in combination with pemetrexed and platinum-based chemotherapy, for the first-line treatment of adults with unresectable advanced or metastatic malignant pleural mesothelioma.
Pleural mesothelioma, which develops in the lining of the lungs, accounts for around 75% of all cases of malignant mesothelioma, a type of cancer that originates in the lining of certain parts of the body.
This approval is based on the results of a Phase III trial, in which Keytruda combined with chemotherapy demonstrated a statistically significant improvement in overall survival compared with chemotherapy alone.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Pleural mesothelioma, which develops in the lining of the lungs, accounts for around 75% of all cases of malignant mesothelioma, a type of cancer that originates in the lining of certain parts of the body.
This approval is based on the results of a Phase III trial, in which Keytruda combined with chemotherapy demonstrated a statistically significant improvement in overall survival compared with chemotherapy alone.
Copyright (c) 2024 CercleFinance.com. All rights reserved.